Administering TMAO to mouse models of HFD-induced NAFLD and aggravated liver steatosis by shifting the hepatic BA composition to FXR-antagonism and inhibiting the hepatic FXR signaling that consequently upregulates lipogenesis (Tan et al., 2019). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.